Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Financials early next week?

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Aug 23, 2022 5:48pm

312 Views

Post# 34915516

RE:RE:RE:RE:Financials early next week?

Hi ScienceFirst - here's the 270 day table from the May 30 MD&A:

	270 Days
CR	10
PR	2
NR	14
Pending	15
Total	41

If you remove the 3 phase 1 patients you get

	270 Days
CR	8
PR	2
NR	13
Pending	15
Total	38

Since we know 30 patients will reach 270 days by the end of August, we should get 270 day results from 7 of the pending (8+2+13+7=30). As of the end of August, if none of 7 are CR the 270 day CR rate will be 27%. If all of the 7 are CR we will have a 270 day CR rate of 50%

If we want to see what 270 day results look like without the 12 undertreated patients we can remove 12 patients from the NR category. This gives us 270 day CR results of, at a minimum 8 out of 18 = 44% CR or at a maximum 15 out of 18 = 83% CR, depending on how many of the additional 7 patients achieve CR.

ScienceFirst wrote:
Eoganacht... Nice input.

If we remove the first 12 undertreated patients from those 30 ones, we would have 60% of those 30 ones that would belong to the optimized group.

If TLT could break us down their data, we could potentially see a trend for this optimized group 60% into the 450-day DR target, giving us a much more predictable picture of where we could land as we add more patients over time.

More patient data evolving toward the DR target will be pivotal on the share price.